Titles
- Choosing wisely: selecting outcomes for comparative effectiveness research on services for adults with disabilities1
- Citizen petitions and petitions for stay of action subject to section 505(q) of the Federal Food, Drug, and Cosmetic Act1
- Closing postpartum coverage gaps and improving continuity and affordability of care through a postpartum Medicaid/CHIP extension1
- Closing the "doughnut hole" has helped protect millions of Medicare beneficiaries from high drug costs1
- Community health centers and Medicaid payment reform: emerging lessons from Medicaid expansion states1
- Community health centers and the President’s HIV Initiative: issues and challenges facing health centers in high-burden states and communities1
- Community health centers continued to expand patient and service capacity in 20171
- Community health centers ten years after the Affordable Care Act: a decade of progress and the challenges ahead1
- Community health centers' experiences in a more mature ACA market1
- Community health centers: a 2013 profile and prospects as ACA implementation proceeds1
- Community health centers: growing importance in a changing health care system1
- Comparative effectiveness research: Patient-Centered Outcomes Research Institute and HHS continue activities and plan new efforts : report to Congressional committees1
- Comparing health insurance reform options: from "building on the ACA" to single payer1
- Competing demands: operational imperatives for the California Health Benefit Exchange1
- Compliance policy for certain compounding of oral oxitriptan (5-HTP) drug products for patients with tetrahydrobiopterin (BH4) deficiency: immediately in effect guidance for industry1
- Compounded drug products that are essentially copies of a commercially available drug product under Section 503A of the Federal Food, Drug, and Cosmetic Act1
- Compounded drug products that are essentially copies of approved drug products under Section 503B of the Federal Food, Drug, and Cosmetic Act1
- Compounding certain ibuprofen oral suspension products under section 503B of the Federal Food, Drug, and Cosmetic Act1
- Considerations for a local health insurance option in Medicaid non-expansion states1
- Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products: guidance for industry1